19
Oct
2020
Getting Ready for the Next Pandemic With a Comprehensive Response
The progress in developing therapies and vaccines for COVID-19 has been extraordinary, and has received extraordinary attention. But there’s another good news story beginning to emerge, about our widening array of defenses against bacterial infectious disease. On the clinical front in the past month, developers have announced positive Phase III trials in difficult diseases that have been marked with prior... Read More
15
Oct
2020
J&J Vaccine Study Paused, Lilly Antibody Paused, and Regeneron’s Ebola FDA Approval
It’s hard to tell yet whether the J&J vaccine and Eli Lilly antibody trials are suffering from momentary blips, or something more serious on the safety front. The AstraZeneca vaccine trial has been stuck on pause in the US since September, which seems like a rather lengthy delay in pandemic terms. Let’s hope they all get back in the saddle... Read More
15
Oct
2020
Corporate Leaders Face Pressure from Investors, Regulators to Act on Diversity
Over the summer, when George Floyd’s horrific death and the disparities of the pandemic combined to spur a new national reckoning with systemic racial injustice, many CEOs issued statements. Many insisted they would do more than talk – they’d take action in day-to-day business against structural inequalities. Those loud pronouncements of action are fading fast. The reverberations of their disquietude... Read More
14
Oct
2020
RayzeBio Snags $45M to Reimagine Targeted Radiotherapies for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Oct
2020
An Especially Inspiring Nobel Prize, and a Sign of More Work to Do
A historic moment for women in science Early in the morning of Wednesday, Oct. 7, we heard news that buffered the impact of the chaos and tragedy of this year. For the first time in history, women almost matched men for Nobel Prize awards across all categories. One in particular stood out. Two women shared the award in Chemistry: Dr.... Read More
12
Oct
2020
Looking at Cancer From a Different Angle: Pearl Huang on The Long Run
Today’s guest on The Long Run is Pearl Huang. Pearl is the CEO of Cambridge, Mass.-based Cygnal Therapeutics. Cygnal is a startup dedicated to developing cancer drugs based on some fairly new understanding of the Peripheral Nervous System. For years, scientists assumed that the PNS was merely a conduit of the central nervous system. But what if the PNS is... Read More
8
Oct
2020
A Historic Nobel for CRISPR, Pfizer Sticks Up for FDA, & a CDC Legend Speaks
What a time to be alive in biomedicine. Catch up on the main events in Frontpoints. The Babe Ruth of Public Health Speaks Out William Foege is in his mid-80s. There’s a genome sciences building at the University of Washington named after him because Bill Gates gave money to build it, and he wanted it named after a scientific hero.... Read More
7
Oct
2020
Learning From COVID-19: The Lessons For Real World Data
The COVID-19 crisis created an urgent need for healthcare data. For starters, it was necessary to characterize the spread of the pandemic. Quickly, reports were needed on the capacity of healthcare facilities responsible for care of the severely afflicted. Then there was the urgent need to assess the trajectory, and outcomes, of patients admitted to hospitals. The profound difficulty our... Read More
7
Oct
2020
Seeing COVID-19 in Context: Applying Spatial Biology to the Lungs
It’s worth looking back on what is known about the SARS-CoV-2 virus, which was first detected in the US in mid-January, when a man traveled from Wuhan, China to Seattle. Nearly 10 months later, a tremendous amount of knowledge has been gathered about the virus, how it is transmitted, and the disease symptoms it causes. We know, for instance, the... Read More
1
Oct
2020
FDA Commissioners Speak Out, An Antibiotic Incentive Proposal and a Drug Price Grilling
Rummaging around in the garage can be about more than just tossing out junk. Going through old files lately, I found a printout from the Carnegie-Knight Task Force in 1997. That was the year I graduated from college and went to work as a local newspaper reporter. The task force, convened by the Project for Excellence in Journalism, was wrestling... Read More
30
Sep
2020
COVID-19 Diagnostic Testing Needs To Be Open, Not Closed
The U.S. already has the real-time PCR infrastructure to run tens of millions of tests per day. Why don’t we use that capacity? Our consumer electronics companies are constantly marketing the newest one-touch, automatic machine. They make it sound so simple, so alluring, so irresistible. Think of our smartphones and watches. That might partly explain the administration’s instant embrace of... Read More
28
Sep
2020
Small Molecules Against RNA Targets: Jennifer Petter on The Long Run
Today’s guest on The Long Run is Jennifer Petter. She is the founder and chief scientific officer of Waltham, Massachusetts-based Arrakis Therapeutics. Jennifer is a medicinal chemist who has spent her career thinking about how to make small molecules with all the classic Lipinski “Rule of 5” characteristics against protein targets. Five years ago, when she was looking for a... Read More
24
Sep
2020
Illumina’s Bet on Early Cancer Detection & ESMO Highlights
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Sep
2020
How Lunch with Bill Gates, Sr. Changed My Life
“I’m gonna have the halibut and chips. And a medium vanilla milkshake. What about you, Thong?” I looked up at my towering companion as he peered down at me with a gentle smile. I’m about 5-foot-8, and he was about 6-foot-7. I quickly scanned the menu board, then made my choice. “You know, Mr. Gates, I think I’m going to... Read More
22
Sep
2020
Designing ‘Hyperstable Minibinders’ Against SARS-CoV-2: Q&A With David Baker
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Sep
2020
What We Know About COVID-19, and What We Don’t
He or she will have had fever and chills for the past few days, severe fatigue, muscle aches, and cough. They have no interest in food. They will have felt short of breath when doing the mildest of tasks, such as walking upstairs in their house. They might have had some lightheadedness and may say that they feel chest pain... Read More
17
Sep
2020
A Tribute to Bill Sr.
Before diving into a big week in biotech, let’s pause to think about the life of a tremendous human being we can learn from. RIP Bill Gates Sr. died at age 94. He had Alzheimer’s. The father of one of the world’s richest men was a prominent lawyer, and deeply engaged civic-minded figure in my hometown of Seattle. The older... Read More
16
Sep
2020
Graphite Bio Secures $45M Series A To Advance Targeted Gene Editing Therapy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Sep
2020
America, the Engine of Biomedical Discovery, Should Be Trump’s ‘Most Favored Nation’
Imagine if John F. Kennedy had stepped to the podium at Rice University on Sept. 12, 1962 and said: “We choose to go to the moon. We don’t know how to do it, but we’ll pay what seems like a fair price for one rocket — something like what the Soviets are paying their people.” That wouldn’t inspire anyone. It... Read More
14
Sep
2020
Attralus Secures $25M Series A to Diagnose and Treat Amyloidosis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.